RAS Meetings and Videos
Upcoming Seminars, Workshops, and Conferences
The Regulation and Function of Small GTPases
Sunday – Friday, June 23-28, 2019, Olean, New York, USA
The RAS Superfamily and Related Pathways in Health and Disease
Thursday - Friday, May 16-17, 2019, Santander, Cantabria, Spain
Previous Seminars, Workshops, and Conferences
Targeting RAS Mutant Cancers
Sunday - Wednesday, December 9–12, 2018, San Diego, USA
5th NCI Pancreatic Cancer Symposium
Tuesday - Wednesday, October 2–3, 2018, Bethesda, Maryland, USA
Frontiers in RAS Pathobiology and Drug Discovery
Thursday - Sunday, September 13–16, 2018, Stratton, Vermont, USA
Small G Proteins in Cellular Signaling and Disease
Monday - Thursday, July 9–12, 2018, Cambridge, UK
Videos and Recorded Webcasts
The NCI RAS Initiative was featured on National Public Radio on March 9, 2018. Photo credit: Richard Harris/NPR Used with permission.
At the recent Annual Meeting of the American Association for Cancer Research, Frank McCormick, leader of the NCI RAS Initiative, summarizes recent RI activities.
Bert Vogelstein reflects on why we can cure cancer in mice but not so well in people, and on the sources of mutations in cancer.
As drugs that attack RAS directly become available, cancers will inevitably develop resistance. What Charles Sawyers tells us about resistance mechanisms in prostate cancer gives us hope that resistance to RAS therapies can be overcome.
Dr. Frank McCormick, UCSF, describes recent progress in understanding of connections between KRAS and stem-ness. June 11, 2015, at the National Cancer Institute, Frederick, Maryland.
All the scientific presentations from the 2015 Annual Meeting of the American Association for Cancer Research in Philadelphia, USA that are available for viewing without charge may now be found on the AACR web site.
Dr. Matt Holderfield of the Frederick National Lab describes the development of multiple drug screening platforms targeting KRAS in the NCI RAS Initiative. April 21, 2015 at the AACR Annual Meeting, Philadelphia, USA.
Dr. Michael Stratton of the Welcome Trust Sanger Institute, Cambridge, UK describes new insights into the mutational processes that drive cancers. (Dr. Stratton's sciencific remarks begin five minutes into the video.) April 19, 2015 at the AACR Annual Meeting, Philadelphia USA.
Dr. Susan Bates of the NCI's Developmental Therapeutics Branch and Dr. Frank McCormick, science advisor to the NCI RAS Initiative, describe the impact of RAS mutations on human health, and new information on regulation of RAS signaling. February 10, 2015 at the National Cancer Institute, Bethesda, Maryland
Dr. Mariano Barbacid of the Centro Nacional de Investigaciones Oncologicas in Madrid, Spain describes how engineered mouse models are being used to understand the role of KRAS in human cancers. November 12, 2014, at the Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, Maryland
Dr. Cyril Benes of Massachusetts General Hospital and Harvard Medical School describes his lab's efforts to correlate genotypes and other molecular data with drug sensitivities in hundreds of cell lines derived from human tumors. October 17, 2014, at the Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, Maryland
2014 RAS Symposium Presentations
The following ten presentations were presented at the symposium "Targeting RAS Now for Future Cancer Therapy," held at the University of California, San Francisco (UCSF), June 19 and 20, 2014
Dr. Frank McCormick, Director of the UCSF Cancer Center and advisor to the RAS Initiative at FNLCR, describes what we do not know about RAS-driven cancers.
Dr. Kevan Shokat, UCSF, describes how his group developed a small molecule that directly targets a KRAS mutant found in many human cancers.
Dr. Stephen W. Fesik, Vanderbilt-Ingram Cancer Center, describes how fragment-based methods can be applied to trying to drug the undruggable.
Dr. James A. Fagin, Memorial Sloan Kettering, describes mechanisms underlying signaling downstream of RAS proteins.
Dr. Deborah Morrison, NCI, describes inhibitors of RAF-RAF dimerization.
Dr. Julian Downward, the Cancer Research UK London Institute, describes interactions between PI3K and KRAS, synthetic lethal screens, and circulating tumor DNA.
Dr. Kevin Shannon, UCSF, describes how dominant oncogenes, Notch and KRAS, are down-regulated in drug-resistant leukemias.
Dr. Erica Jackson, Genentech, describes enrichment of cells with stem cell markers in populations of lung cancer cells.
Dr. Eric Collisson, UCSF, describes genomics and patient studies that highlight the role of NF1 loss in human cancers.
Dr. Frank McCormick, science advisor to the RAS Initiative at FNLCR, describes work in his lab at UCSF to develop new tools and identify new targets relevant to KRAS cancers.
Dr. Frank McCormick describes recent experiments to understand KRAS signaling in cancer at the AACR Annual Meeting, April 5, 2014, San Diego, California USA
Dr. Harold Varmus and other scientific leaders discuss the RAS Initiative at the Frederick National Laboratory for Cancer Research. September 24, 2013, National Cancer Institute, Bethesda, Maryland USA
Dr. Channing Der gives a perspective on past and present attempts to drug mutant KRAS. June 21, 2013, National Cancer Institute, Bethesda, Maryland USA
Structural Aspects of RAS GTPases
Dr. Alfred Wittinghofer explains how solving the three-dimensional structure of RAS and other G-proteins allowed him to understand the conserved mechanism by which G-proteins can act as switches. June 19, 2011
In the second part of Dr. Wittinghofer's talk he explains the link between GTPases and disease. June 19, 2011